| Literature DB >> 26893674 |
Zhikui Wang1, Zhaoxia Wang1, Zhongqi Zhou1, Yueqin Ren1.
Abstract
Despite clear cell sarcoma of the kidney (CCSK) being the second most common renal tumor in children, its mechanism has not yet been fully investigated. The aim of the present study was to investigate the potential role of vascular endothelial growth factor A (VEGFA) in CCSK development. Following preprocessing of the original GSE2712 data, the differentially-expressed genes (DEGs) between 14 CCSK and 3 fetal kidney samples were identified through Significance Analysis of Microarrays, using the R package. Pathway enrichment analysis was then performed on the DEGs. A protein-protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins database and the DEGs that were enriched in the most significant pathways. Following this, gene ontology analysis was performed on the VEGFA-associated genes, whilst transcription factor binding site analysis was conducted on the hot genes. A total of 2,681 DEGs, including 543 upregulated and 2,138 downregulated genes, were identified, and these were significantly enriched in pathways associated with cancer and focal adhesion. Furthermore, VEGFA, integrin β1, integrin αV, v-akt murine thymoma viral oncogene homolog 1 and endothelial growth factor receptor were identified as hot genes in the PPI network. In addition, the upregulated VEGFA-associated genes, cyclin D1 and cyclin-dependent kinase inhibitor 1B, affected kinase regulation, and the downregulated VEGFA-associated genes, receptor tyrosine-protein kinase erbB-2, mesenchymal-epithelial transition tyrosine kinase receptor and kinase insert domain receptor, were enriched in the protein tyrosine kinase process. It was identified that VEGFA was regulated by restorer of fertility, erythromycin resistance methylase, GA binding protein subunit α, norepinephrine transporter, nuclear factor κB and Sp2 transcription factor genes. Overall, VEGFA and its associated genes serve important roles during CCSK development, and alongside transcription factors, they may function as novel therapeutic targets for disease treatment.Entities:
Keywords: clear cell sarcoma of the kidney; differentially-expressed genes; pathway analysis; protein-protein interaction network; transcription factor binding site analysis
Year: 2015 PMID: 26893674 PMCID: PMC4734171 DOI: 10.3892/ol.2015.4006
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Most significant pathways in which the differentially-expressed genes were enriched (P<0.05).
| Term | Count | P-value | Genes | Gene regulation |
|---|---|---|---|---|
| hsa05200: Pathways in cancer | 33 | 1.35×10−6 | WNT5A, FGFR1, FGF18, WNT5B, FGF9, PDGFA, FOXO1, FGF13, ZBTB16, KIT, GLI2, GLI1, AKT1, IGF1R, WNT4, CASP3, CASP8, RUNX1, CEBPA, EGFR, AR, BMP2, TCF7, CTBP2, EPAS1, CDK6, CDKN1A, CCND1, CDKN1B, PDGFRA, PTCH1, WNT11, PIAS1 | Upregulated |
| hsa04510: Focal adhesion | 50 | 1.03×10−5 | PAK4, ILK, PDGFC, AKT3, ACTN4, ROCK1, ROCK2, FLNB, VASP, PRKCB, PPP1CA, LAMC3, VEGFA MAPK3, RELN, LAMC1, COL1A1, PARVB, PARVA, IBSP, CAV2, ERBB2, TNC, ITGB1, PXN, MYL9, LAMB2, DOCK1, ITGAV, SOS2, COL6A3, THBS1, SPP1, COL4A4, VAV3, MET, ITGA2, MYLPF, MYL12B, ITGA3, MYL12A, ITGA4, CAPN2, COL4A6, KDR, LAMA1, LAMA5, ITGA8, ITGA7, MYLK | Downregulated |
Count, number of genes enriched in the pathway.
Figure 1.PPI network of the differentially-expressed genes enriched in the two significant pathways. Diamonds indicate genes associated with vascular endothelial growth factor A (VEGFA); circles indicate genes not associated with VEGFA; red indicates upregulated genes; green indicates downregulated genes; and larger diamonds indicate hot genes with >30 related genes.
Significant GO terms for vascular endothelial growth factor A-related genes (P<0.05).
| Category | Term | P-value | Genes | Regulation |
|---|---|---|---|---|
| GOTERM_MF_FAT | GO:0016538 cyclin-dependent protein kinase regulator activity | 1.37×10−2 | CCND1, CDKN1B | Upregulated |
| GOTERM_MF_FAT | GO:0019887 protein kinase regulator activity | 4.08×10−2 | CCND1, CDKN1B | Upregulated |
| GOTERM_MF_FAT | GO:0019207 kinase regulator activity | 4.08×10−2 | CCND1, CDKN1B | Upregulated |
| GOTERM_MF_FAT | GO:0004714 transmembrane receptor protein tyrosine kinase activity | 3.39×10−4 | ERBB2, MET, KDR | Downregulated |
| GOTERM_MF_FAT | GO:0004713 protein tyrosine kinase activity | 1.48×10−3 | ERBB2, MET, KDR | Downregulated |
| GOTERM_BP_FAT | GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway | 7.93×10−4 | ERBB2, MET, KDR | Downregulated |
| GOTERM_BP_FAT | GO:0007167 enzyme-linked receptor protein signaling pathway | 1.71×10−3 | ERBB2, MET, KDR | Downregulated |
| GOTERM_BP_FAT | GO:0006928 cell motion | 5.01×10−3 | ERBB2, VASP, KDR | Downregulated |
MF, molecular function; BP, biological process; GO, gene ontology.
Figure 2.Transcription factor binding site analysis for hot genes. Diamonds indicate overexpressed TF names; red circles indicate upregulated genes; green circles indicate downregulated genes and blue lines indicate interactions between transcription factors and hot genes.